Search Within

Matthew J Matasar

  1. "Center for Hematologic Malignancies"
  2. "Andrew Zelenetz"
  3. "Executive Committee, Center for Hematologic Malignancies"
  4. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (30)
  2. Journal Article (16)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (47)
  2. Department of Medicine (47)
  3. Epidemiology and Biostatistics (47)
  4. Executive Committee, Center for Hematologic Malignancies (47)
  5. Hematologic Malignancies, Division of (47)
  6. Lymphoma (47)

More Groups

People
  1. Andrew Zelenetz (47)
  2. Anas Younes (44)
  3. Anita Kumar (41)
  4. Ariela Noy (41)
  5. David Straus (41)
  6. Steven Horwitz (41)

More People

Years
  1. 2023 (1)
  2. 2022 (3)
  3. 2021 (8)
  4. 2020 (6)
  5. 2019 (8)
  6. 2018 (3)

More Years

Publications
  1. Blood (22)
  2. Hematological Oncology (8)
  3. Blood Cancer Journal (5)
  4. Blood Advances (3)
  5. Journal of Clinical Oncology (3)
  6. Clinical Cancer Research (2)

More Publications

Publishers
  1. American Society of Hematology (25)
  2. Wiley Blackwell (8)
  3. Nature Publishing Group (5)
  4. American Society of Clinical Oncology (3)
  5. American Association for Cancer Research (2)
  6. Elsevier Inc. (2)

More Publishers

Results (47)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: An open label phase II study
    Research Letter

    Qualls, D.; Noy, A.; Straus, D.; Matasar, M.; Moskowitz, C.; Seshan, V.; Dogan, A.; Salles, G.; Younes, A.; Zelenetz, A. D.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
    Journal Article

    Bobillo, S.; Joffe, E.; Sermer, D.; Mondello, P.; Ghione, P.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; more...
    Blood Cancer Journal (2021)

    Fulltext@MSK | Save